This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Bulevirtide for chronic hepatitis delta virus infection

< Back

Bulevirtide for chronic hepatitis delta virus infection


Infectious Disease and Immunisation

January 2020

Bulevirtide is in clinical development for the treatment of chronic hepatitis Delta virus infection in adult patients with compensated liver disease. Hepatitis D is a viral infection of the liver that is dependent on the patient already being infected with hepatitis B virus. The co-infection is thought to be more severe and cause more damage to the liver than hepatitis B alone. Currently there are limited treatment options for the treatment of patients with chronic hepatitis D virus infection.
Bulevirtide is a synthetic protein that is designed to specifically to bind to and block, a receptor present on liver cells. This receptor is essential to hepatitis B and D viruses entering and infecting the liver cells. By blocking the entry of hepatitis D virus, bulevirtide limits the virus ability to spread and replicate, reducing the symptoms of infection. If licensed, bulevirtide will become the first-in-class potent entry inhibitor offering a new therapeutic option for patients suffering from chronic hepatitis delta virus infection for whom limited therapeutic regimens are available.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts